We started to build a roadmap with many milestones that we wanted to achieve for this continent. All of this has to be built from the…
In Conversation
DIA today is a vastly different organization than it was. Our emphasis on catalyzing thought leadership and applying our global platform and channels to convene, conduct…
The issue of health is simply not a priority for the government. This is evident through the way they minimise many important aspects of the process…
The opportunity is huge for the government to bring in a universal health insurance scheme. As the private industry, we need to participate in helping make…
AbbVie’s increased focus on Egypt has been driven by the reforms that have been happening here, including the creation of the Egypt Drug Authority (EDA), the…
In Mexico 85 percent of the medicines consumed by the population are produced in the country itself. For this reason, Mexico is considered one of the…
Regulators, the industry and people in charge of the public healthcare systems are all pushing for regulatory innovation. The European Commission’s (EC) work is interesting because…
At EVA Pharma, we are trying to be a pan-African company and, while we already have a presence in Western Europe and the Middle East, we…
LatAm has an ethnically diverse population, strong doctor-patient relationships, and great clinical research centres, all of which are increasingly attracting the eye of our member companies…
We are looking to bring in about 11 to 13 new innovative products in the upcoming three years, which is very exciting for the country.
Unlike other European countries which have capped their clawback system (Portugal) or replaced it with a discount scheme (Romania), the Greek clawback mechanism is out of…
Empathetic dialogue and an understanding of our shared goals, and the value that innovation brings to health systems are critical, as is facilitating enabling infrastructure, creating…
